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Abstract
During angiogenesis, the development of new blood vessels from existing vessels,
there must be tight regulation between a leading tip cell and trailing stalk cells during
vascular patterning. Lateral inhibition produced by Notch signaling is central to the
specification and maintenance of tip and stalk cells in growing angiogenic sprouts. The
Notch pathway is activated by the ligand Delta at adherens junctions between tip and
stalk cells. Despite the centrality of Delta/Notch signaling to angiogenesis, relatively little
is known about the mechanism of this signaling event. It has been proposed that the force
generated by the Notch bound Delta ligand exposes a cleavage site necessary for Notch
activation. Here, we show for the first time in endothelial cells that the proteins Epsin
homology domain protein 2 (EHD2) and EHD2 binding partner 1 (EHBP1) regulate
Delta like ligand 4 (Dll4) endocytosis by tethering its caveolar endocytic pit to the actin
cytoskeleton.

ii

Acknowledgements
I am very appreciative of all the mentoring and support I have received from Dr.
Kushner throughout my time in his lab. He inspired me as an undergraduate to embrace
my curiosity, pursue research, and gave me the extra push to go to graduate school. I’d
also like to thank everyone in Dr. Kushner’s lab for being so supportive and helpful
during my research. Thank you to my family for always being there for me, I could not
have done this without any of you. Special thanks to my dad for the long hours at the
dining room table helping me code. Thank you to Jennifer Bourne at University of
Colorado Anschutz for her contribution in TEM imaging and to Stryder Meadows at
Tulane University for collaborating with us and sharing his investigations into EHD2.

iii

Table of Contents
Abstract ............................................................................................................................... ii
Acknowledgements ............................................................................................................ iii
Table of Contents ............................................................................................................... iv
List of Figures ..................................................................................................................... v
Chapter One: Introduction ................................................................................................. 1
Chapter Two: Materials and Methods................................................................................. 9
Zebrafish Handling and Experimental Methods ....................................................... 9
Cell Culture ............................................................................................................. 11
pHrodo internalization assay................................................................................... 13
Microscopy ............................................................................................................. 14
Immunohistochemistry ........................................................................................... 15
Western Blot ........................................................................................................... 15
Pharmacological Treatment .................................................................................... 16
RNA-Sequencing .................................................................................................... 16
Quantification and Statistical Analysis ................................................................... 17
Chapter Three: Results ...................................................................................................... 19
Loss of EHBP1 and EHD2 produces vascular defects in zebrafish........................ 19
EHBP1 and EHD2 phenocopy Notch loss of function ........................................... 22
EHBP1 and EHD2 organize around membranous Dll4 independent of clathrin.... 27
EHBP1, EHD2, and caveolin localize to adherens junctions in 3D sprouts ........... 31
Loss of EHBP1 and EHD2 blunts Dll4 endocytosis and caveolar integrity ........... 34
RNA-seq analysis of EHBP1 deficient cells ........................................................... 38
Chapter Four: Conclusions ............................................................................................... 44
References ......................................................................................................................... 50
Appendix A ....................................................................................................................... 58
Appendix B ....................................................................................................................... 61

iv

List of Figures
Figure 1. Notch signaling regulates lateral inhibition during angiogenesis........................ 2
Figure 2. Domains of Notch1 and Dll4. .............................................................................. 3
Figure 3. Domain architecture of EHD2 and EHBP1. ........................................................ 7
Figure 4. Global deletion of EHBP1 and EHD2a/b produces vascular defects in zebrafish
........................................................................................................................................... 20
Figure 5. Vascular excision of EHBP1 produces vascular defects in zebrafish ............... 21
Figure 6. 𝛾-secretase inhibitor produces vascular defects in zebrafish. ........................... 23
Figure 7. Notch loss of function in EHBP1 and EHD2 KO zebrafish. ............................. 24
Figure 8. EHBP1 and EHD2 preferentially express in tip cells during angiogenesis....... 26
Figure 9. EHBP1 and EHD2 organize around Dll4 independent of clathrin .................... 28
Figure 10. EHBP1 and EHD2 organize around Dll4 dependent on actin ......................... 30
Figure 11 EHBP1 and EHD2 organize around Dll4 dependent on caveolin .................... 32
Figure 12. EHBP1, EHD2, and Caveolin localize to adherens junctions in 3D vascular
sprouts ............................................................................................................................... 33
Figure 13. Endocytosis of Dll4 and NECD are dependent on EHBP1 and EHD2. .......... 36
Figure 14. Loss of EHBP1 and EHD2 result in Notch downregulation and loss of
caveolar structure. ............................................................................................................. 38
Figure 15. RNA-Seq analysis of loss of EHBP1 in HUVEC. .......................................... 40
Figure 16. Gene ontology analysis of differentially regulated genes reveals cell-wide
signaling disruptions. ........................................................................................................ 42
Figure 17. Model of EHBP1 and EHD2 generating force on caveolar pit ....................... 47

v

Chapter One: Introduction
Angiogenesis is the process in which a new blood vessel develops from an
existing vascular bed. During this process, in response to a chemotactic gradient of
vascular endothelial growth factor (VEGF), a single endothelial cell in a group must
identify itself as a tip cell. This tip cell will then lead the charge towards the VEGF-A
signal, pulling behind it a trail of stalk cells in the growing vascular sprout (Figure 1A).
Tip and stalk each have distinct morphological and functional identities: the tip is defined
by its spiny, branching filopodia reaching forward as the tip migrates; the stalk is defined
by its smoothened appearance and suppressive stability (Gerhardt et al. 2009). In order
for proper angiogenic growth to proceed, the maintenance of tip/stalk cell specification is
paramount.
Central to tip/stalk cell specification is the Notch signaling pathway. There are 4
Notch receptors found in mammals (Notch1-4) (Quillard et al. 2013). Differences
between the 4 receptors are mainly in the number of EGF repeats (Sander, Krysinska, and
Powell 2006). Although each Notch receptor is present in the vasculature, Notch1 is the
predominant receptor involved in angiogenesis (Liu et al. 2003). Notch is a
transmembrane protein composed of an extracellular domain (NECD) and an intracellular
domain (NICD). Cells enriched in Notch with high Notch activation will adopt a stalk
cell identity, whereas a cell deficient in Notch or Notch signaling will adopt a tip cell
identity (Figure 1, Benedito et al. 2009, Blanco et al. 2013).
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Figure 1. Notch signaling regulates lateral inhibition during angiogenesis. (A) A
growing angiogenic sprout migrates towards a chemotactic gradient, with tip cell (blue)
forming spiny, reaching branches and stalk cell (grey) appearing smooth. (B) With
increased Delta and reduced Notch signaling, more cells will adopt a tip cell fate; there is
low stability in the stalk and increased sprouting. Conversely, with high Notch signaling
increased lateral inhibition will lead to low sprouting.
Importantly, the NECD is composed of 36 Epidermal Growth Factor (EGF) repeats and a
Negative Regulatory Region (NRR) domain (Figure 2). The NRR contains three Lin-12Notch (LNR) repeats that interact with a heterodimerization domain (HD). There is a
cleavage site termed S1 on the NECD (Figure 2). The functional significance of this
cleavage site is debated, as it has been found to be highly variable between the 4
mammalian Notch variants and is unnecessary for neither Notch binding to its ligand nor
Notch activation (Gordon et al. 2009). Obscured within the interaction between LNR and
HD at a resting state is a second cleavage site (termed S2) (Figure 2). When exposed, the
2

B.

NLS
ANK
RAM
TM
HD

S3

S2
S1

EGF 1-36

LNR
NECD

DSL
EGF

NICD

PEST

A.

Figure 2. Domains of Notch1 and Dll4. (A) Notch extracellular domain (NECD) is
composed of 36 Epidermal Growth Factor (EGF) repeats, 3 Lin12 -Notch Repeats
(LNR), and the heterodimerization domain (HD). The S1 cleavage site is in the NECD.
The S2 cleavage site is hidden by the interaction between the LNR and HD. The Notch
intracellular domain (NICD) is composed of the transmembrane domain (TM), RBPJ/CBF1-associated module (RAM), Ankyrin (ANK) repeats, nuclear localization
sequence (NLS), and a proline/glutamic acid/serine/threonine (PEST) rich domain. The
S3 site is located in the TM. (B) Dll4 is composed of a Delta-Serrate Lag (DSL) domain
and 8 EGF repeats.

S2 cleavage site is cleaved by a disintegrin and metalloprotease (ADAM) complex. This
cleavage event necessarily precedes cleavage by 𝛾-secretase at the S3 cleavage site to
release the NICD. Once free, the NICD translocates to the nucleus, binding the
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transcription factor CSL, also known as RBP-J, to upregulate downstream genes that
promote lateral inhibition (Gordon et al. 2008). Activation of Notch is inhibitory.
Activation of lateral inhibition in the stalk cell results in a cascade of events to maintain
stalk cell identity. The stalk cell acts to remove VEGF receptors from the membrane and
repress the expression of Delta (Mack and Iruela-Arispe, 2018).
Conversely, in the tip cell, VEGF is enriched on the membrane and Delta is
upregulated. While this describes a binary fate alternating in adjacent cell types,
endothelial cells also undergo lateral induction through which the stalk cell fate is
directionally propagated through all stalk cells. By this mechanism, a positive feedback
loop is created in which each stalk cell both activates Notch signaling and promotes
Notch signaling (Sjöqvist and Andersson, 2019).
The activity of Notch (or lack thereof) is first dictated by its binding to one of two
families of proteins at the apical junction between two endothelial cells: Jagged and
Delta. In structure, Jagged and Delta are seemingly very similar to
one another; each bind Notch EGF repeats 11-13 through their own EGF repeats
mediated by the Delta-Serrate Lag (DSL) domain on both Delta and Jagged (Fiúza and
Arias 2007, Figure 2). Despite the structural similarity to one another,
binding of Notch to Jagged and Delta have opposite signaling consequences (Benedito et
al. 2009). Binding of Notch to Jagged inhibits Notch signaling; binding of Notch to Delta
activates Notch signaling. This opposing role of signaling of Delta and Jagged is not well
defined in literature, but has been proposed to be a result of differential Notch
downstream targets (e.g. “non-canonical” pathway activation) or differential Fringe
glycosylation of Delta and Jagged (Le Gall et al, 2008; Panin et al, 2002).
4

It has been shown that Delta endocytosis regulates Notch activation (Chintis,
2006). One proposed mechanism for this activation is the application of a mechanical
force generated by Delta/NECD transendocytosis into the ligand-containing cell. This
force has been shown to be on the order of 19 pN per single bond (Shergill et al. 2012)
and is necessary to force apart the LNR/HD interaction, thus exposing the S2 site for
cleavage and subsequent S3 cleavage. Studies on the mechanical force generated by
Notch/Delta to date have only focused on Delta like ligand 1 (Dll1) (Shergill et al. 2012,
Meloty-Kapella et al. 2012). However, Dll1 and Delta like ligand 4 (Dll4) are
functionally different; For instance, Dll4 mutant mice die embryonically while Dll1
mutant mice survive until birth (Gessler, 2009). Despite the prominence of Delta like
ligand 4 (Dll4) in angiogenesis, the endocytic force provided by the Dll4 endocytic
vesicle and the precise mechanism of Dll4 endocytosis remains unknown.
Clathrin mediated endocytosis is the process by which cargo is packaged into a
coated pit. First, cargo bound to an AP-2 receptor recruits coat proteins to the site of
endocytosis. The coat that surrounds the incoming cargo is composed of clathrin—a
triskelion protein that complexes into a lattice to mold the shape of the incoming vesicle
to a canonical spherical shape (Morris et al 2019). Also recruited to AP-2 is Eps15, an
EH domain binding protein that interacts with Epsin to regulate the endocytosis of
ubiquitinylated proteins (Benmerah et al 1998). As the coated pit becomes fully formed,
two important mechanisms regulate its release from the plasma membrane. First, the
internalized pit is pushed inward by the active polymerization of actin (Kaksonen and
Roux, 2018). Next, dynamin winds around the neck of the endocytic vesicle, constricting
to pinch off the vesicle from the plasma membrane through its GTPase activity
5

(Kaksonen and Roux, 2018). After internalization, the clathrin coated vesicle is uncoated
to release its cargo into the cell.
Caveolin mediated endocytosis displays many similarities to clathrin mediated
endocytosis. As clathrin pits are shaped by clathrin, so too are calveolae shaped by
caveolins and cavins. Caveolins are hairpin shaped proteins embedded into the plasma
membrane (Kovtun et al. 2015). The hairpin shape bends the membrane around them to
form a distinct invagination and are stabilized by cavins. Again, similar to clathrin
mediated endocytosis, caveolar endocytosis also requires the action of actin and dynamin.
Dynamin is required for the scission of the vesicle from the plasma membrane. The
caveolar endocytic vesicle can then interact with actin through the protein Filamin A
bound to caveolin 1 (Cav1) to regulate its intracellular trafficking, such as in the MAPK
signaling cascade (Samaj et al. 2004). However, Echarri and Del Rozo (2015) propose
that there remain yet many unidentified linkers between Cav1 and the cytoskeleton.
In mammals, there are 4 Epsin15 homology domain (EHD) proteins that serve as
dynamin-related GTPases and ATPases. EHD1-4 are each involved in endocytic
processes, although EHD2 stands alone from this group in being the only with a solved
crystal structure and the only to interact with caveolae (Moren et al. 2012). EHD2
contains 4 main functional domains: the N-terminal p-loop, the GTPase(G)-domain, the
helical domain, and the Epsin15 homology (EH) domain. In the cell, EHD2 multimerizes
through an interaction between the G-domain and the EH domain (Hoernke et al. 2017,
Moren et al. 2012, Figure 3). This interaction serves a dual purpose. First, the binding of
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Figure 3. Domain architecture of EHD2 and EHBP1. EHD2 is composed of an Nterminal p-loop, GTPase(G)-domain, helical domain, and Epsin15 homology (EH)
domain. EHBP1 contains 3 NPF motifs which bind the EH domain, a CH domain capable
of tethering actin, and a C-terminal CAAX box.

the G-domain to the EH domain converts the function of the domain from a GTPase to an
ATPase (Melo et al. 2017). Secondly, the multimerization of EHD2 allows it to form a
circular ring around an endocytic vesicle to mediate cleavage (Moren et al. 2012). This
complex has also been shown to localize to Cav1, assisting in caveolin endocytosis
through stabilization of the caveolae pit structure (Torrino et al. 2018).
EHD2’s binding partner, EHBP1, has been much less well characterized. EHBP1
consists of 3 primary functional domains: the NPF motif, the calponin
homology (CH) domain, and the C-terminal CAAX box (Figure 3). The NPF motif is
what binds the EH domain of EHD2. The CH domain tethers the EHD2/EHBP1 complex
to the cytoskeleton. EHBP1 and EHD2 have been found to regulate the clathrin mediated
endocytosis of Transferrin and Glut4 (Guilherme et al. 2003). A similarly strong
interaction between a Dll4 endocytic vesicle complexed to the actin cytoskeleton through
EHBP1 and EHD2 would be required to provide the appropriate mechanical force to
expose the S2 domain on Notch.
While Notch signaling has a wide array of functions throughout development and
in different tissues, its role in vascular development cannot be understated. Improper
7

regulation of Notch can contribute to a wide array of vascular disease processes, and
complete deletion of Notch1 leads to embryonic lethality in mice following severe
vascular defects (Krebs et al. 2000). Among the vascular diseases formed from improper
Notch signaling is hereditary hemorrhagic telangiectasia (HHT). Affecting up to
30/100,000 people, the consequences of arteriovenous malformations (AVMs) in HHT
can range in severity from nosebleeds to fatal stroke (Peacock et al. 2015). Given the
magnitude of Notch signaling in the medical community, the critical lack of
understanding regarding the mechanism and regulators of Dll4 endocytosis represents an
unfortunate blind spot in the community. Equally lacking is a holistic understanding of
the functional relationship between EHD2 and EHBP1 during endocytosis. We seek here
to elucidate the role of EHD2 and EHBP1 in relation to one another, their role in Dll4
endocytosis, and the downstream consequences they pose to Notch signaling as a whole.
We propose that EHBP1 and EHD2 act on caveolar endocytic machinery to tether the
Dll4 endocytic pit to the cytoskeleton and it is through this bridge that the force required
to expose the S2 cleavage site is generated.
In this thesis, we will show that loss of EHBP1 and EHD2 resulted in Notch loss
of function both in vivo and in vitro. EHBP1 and EHD2 organize themselves around Dll4
puncta on the membrane dependent on actin and caveolin-1 and independtly of clathrin.
Endocytosis of a Dll4 antibody and soluble NECD ligand are impaired in the absence of
EHBP1 and EHD2 and caveolar pits lose their structure, supporting the role of EHBP1
and EHD2 to mediate caveolin-mediated endocytosis through tethering to the actin
cytoskeleton. Finally, loss of EHBP1 leads to have cell-wide consequences to signaling
pathways in endothelial cells.
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Chapter Two: Materials and Methods
Zebrafish Handling and Experimental Methods
All zebrafish used in this study were AB strain. Zebrafish housing and protocols
were all approved by the Institutional Animal Care and Use Committee (IACUC, number
946125-1).
Tg(kdrl:GFP) strain previously published by Choi et al. 2007. Tg(fli:LifeActGFP) strain previously published by Hen et al. 2015. Tg(kdrl:mCherry) strain previously
published by Proulx et al. 2010. Tg(kdrl:cre) strain previously published by Bertrand et
al. 2010. Tg(cdh5:gal4FF) strain previously published by Bussmann et al. 2011.
Tol2 transposase RNA was synthesized from pT3TS-Tol2 (Addgene, #31831)
using the MEGAscript™ T3 Transcription Kit (Thermo Fisher Scientific, AM1338) and
stored at -80℃ at a dilution of 100 ng/µl. Injection mixture was prepared on ice
containing 300 ng Tol2 transposase RNA and 500 ng recombinant plasmid and was
brought to 10 µl total volume with 0.1% phenol-red (VWR, 470301-974) in water. 1-4
cell embryos were injected directly into cell with 2 pL injection mixture.
4-guide CRISPR/Cas9 targeted gene KO was performed as outlined by Wu et al
2018. In brief, 4 single guide RNA templates fused to a scaffold were synthesized for
each target gene using HiScribe™ SP6 RNA Synthesis Kit (New England BioLabs,
E2070S). Injection mixture was prepared on ice containing 5 µM Cas9 (PNA Bio,
CP02), 1 µg/µL sgRNA, and brought to 6 µL with 0.1% phenol-red in water. Cas9 and
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sgRNA guides were pre-complexed at 37℃ for 5 mins. 1-4 cell embryos were injected
directly into yolk with 2 pL injection mixture.
Scaffold primer sequence: 5’ –AAAAGCACCGACTCGGTGCCACTTTTTCAA
GTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC– 3’.
Scramble guide sequences: 5’ –TAATACGACTCACTATAGGCAGGCAAAGAATCC
CTGCCGTTTTAGAGCTAGAAATAGC- 3’, 5’ –TAATACGACTCACTATAGGTAC
AGTGGACCTCGGTGTCGTTTTAGAGCTAGAAATAGC- 3’, 5’ –TAATACGACTC
ACTATAGGCTTCATACAATAGACGATGGTTTTAGAGCTAGAAATAGC- 3’, 5’ –
TAATACGACTCACTATAGGTCGTTTTGCAGTAGGATCGGTTTTAGAGCTAGAA
ATAGC- 3’. EHBP1 guide sequences: 5’ – TAATACGACTCACTATAGGGAGTCCCC
ATCGGGTCGTGTTTTAGAGCTAGAAATAGC- 3’, 5’ –TAATACGACTCACTATA
GGCTCATCCGGGTCACCAAAGTTTTAGAGCTAGAAATAGC- 3’, 5’ –TAATACG
ACTCACTATAGGCGACCTATCAGCAGGCCGGTTTTAGAG CTAGAAATAGC3’, 5’ – TAATACGACTCACTATAGGAGATGCCGCAATGAAGGCGTTTTAGAGCT
AGAAATAGC- 3’. EHD2a guide sequences: 5’ –TAATACGACTCACTATAGGCGGT
TCATACAGTAACCGGTTTTAGAGCTAGAAATAGC- 3’, TAATACGACTCACTA
TAGGTTTGCGGAGCACGTAGACGTTTTAGAGCTAGAAATAGC- 3’, 5’ –TAATA
CGACTCACTATAGGAAACGAGCACGCCTTGTAGTTTTAGAGCTAGAAATAGC3’, 5’ -TAATACGACTCACTATAGGCCTTTAAACTTGAAGTCGGTTTTAGAGCTA
GAAATAGC-3’. EHD2b guide sequences: 5’ –TAATACGACTCACTATAGGTCACT
GTCCTGATCACCTGTTTTAGAGCTAGAAATAGC- 3’, 5’ -TAATACGACTCACTA
TAGGTGCTCTCCAGGACCTGGTGTTTTAGAGCTAGAAATAGC- 3’, 5’ –TAATA
CGACTCACTATAGGCGAACAGCTTGCGGTTGTGTTTTAGAGCTAGAAATAGC10

3’, 5’ –TAATACGACTCACTATAGGTTCCTTAGGAGCAACTAAGTTTTAGAGCT
AGAAATAGC- 3.
EHBP1lox fish genotyped using forward primer 5’ –GATGTGTAGAGGAATAC
CGTTCGTATAGC- 3’ and reverse primer 5’ –GTCAGGCTTCACATTGCAGAGTTC3’. EHBP1lox sequence was incorporated to a pME empty backbone for sequencing using
the forward primer 5’ – CGACGGTATCGATAAGCTTGATATCTCTGTGACAGAAT
TGGTCAGTTTGACA- 3’ and reverse primer 5’ –GCGGCCGCTCTAGAACTAGTGG
ATCGCAGCGCAGCTCAGGCAAG- 3’.

Cell Culture
Glass-bottomed imaging dishes were exposed to UV light for 6 minutes and
coated with Poly-D-Lysine (Thermo Fisher Scientific, A3890401) for a minimum of 20
minutes. Dishes were then coated with 15 µg/mL laminin mouse protein (Thermo Fisher
Scientific, 23017015) overnight at 37℃. Cells were plated onto laminin coated dishes for
4-6 hours prior to imaging or fixation. 0.9 µM siRNA (Thermo Fisher Scientific,
s225944, s26959, am4611) was introduced to primary human umbilical vein endothelial
cells (HUVEC) using the Neon® transfection system (Thermo Fisher Scientific).
Adenovirus constructs (tagRFP-EHD2, tagRFP-EHBP1, Emerald-Clathrin) were
created as previously described (He et al. 1998). In brief, constructs were introduced via
Gibson Assembly® (New England BioLabs, E2611) into pShuttle-CMV (Addgene,
#16403). PShuttle-CMV plasmids were then digested overnight with MssI (Thermo
Fisher Scientific, IVGN0244) and purified using E.N.Z.A.® Gel Extraction Kit (Omega
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Bio-Tek, D2500-01). Linearized pShuttle-CMV plasmids were transformed into the final
viral backbone using electrocompetent AdEasier-1 cells (Addgene, #16399). Successful
incorporation of pShuttle-CMV construct into AdEasier-1 cells confirmed via digestion
with PacI (Thermo Fisher Scientific, IVGN0184). 5000 ng plasmid was then digested at
37℃ overnight, then 85℃ for 10 minutes and transfected in a 3:1 polyethylenimine (PEI,
Sigma Aldrich, 408747):DNA ratio into 70% confluent HEK 293A cells (Thermo Fisher
Scientific, R70507) in a T-25 flask (Genesee Scientific, 25-207).
Over the course of approximately 2-4 weeks, fluorescent cells became swollen
and burst or budded off of the plate. Once approximately 50% of the cells had lifted off
of the plate, cells were scraped off and spun down at 2000 rpm for 5 minutes in a 15 mL
conical tube. The supernatant was aspirated, and cells were resuspended in 1 mL DPBS
(Genesee Scientific, 25-508B). Cells were then lysed by 3 consecutive quick freeze-thaw
cycles in liquid nitrogen, spun down for 5 minutes at 2000 rpm, and supernatant was
added to 2 70% confluent T-75 flasks (Genesee Scientific, 25-209). Propagation
continued and collection repeated for infection of 10 15 cm dishes. After collection and 4
freeze thaw cycles of virus collected from 10 15 cm dishes, 8 mL viral supernatant was
collected and combined with 4.4 g CsCl (Sigma Aldrich, 289329) in 10 mL DPBS.
Solution was overlaid with mineral oil and spun at 32,000 rpm at 10℃ for 18 hours. Viral
fraction was collected with a syringe and stored in a 1:1 ratio with a storage buffer
containing 10 mM Tris, pH 8.0, 100 mM NaCl, 0.1 percent BSA, and 50% glycerol.
Primary Human Umbilical Vein Endothelial Cells (Promocell, C-12253) were treated
with virus for 16 hours at a 1/1000 final dilution in all cell culture experiments.
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Fibrin Bead Assay performed according to protocol as outlined by Nakatsu et al.
2007.

pHrodo internalization assay
PHrodo™ iFL Red STP Ester (Thermo Fisher Scientific, P36010) was brought to
10 mM with DMSO. On the day of antibody labeling, pHrodo™ iFL Red STP Ester
was diluted to 2 mM in DMSO (VWR Life Science, 97063-136). Antibody was brought
up in DPBS (2 mg/mL final concentration for Dll4 polyclonal antibody [Thermo Fisher
Scientific, PA5-46974]; 1 mg/mL final concentration for recombinant human Notch-1 Fc
Chimera [R&D Systems, P46531]) and added to 1/10 volume 1 M sodium bicarbonate,
pH 8.5. 3.3 µL of 2 mM pHrodo™ dye was added to the antibody and allowed to react in
the dark for 1 hour with gentle flicking every 15 minutes. While this reaction is
occurring, Zeba™ Spin Desalting Column (Thermo Fisher Scientific, 89882) was washed
3 times with 300 µL DPBS at 1500 x g for 1 minute. After 1 hour, the labeled antibody
solution was loaded into the desalting column and allowed to absorb. DPBS was overlaid
on top of labeled antibody to bring total column load volume to 70 µL and spun at 1500 x
g for 2 minutes. Flow-through stored at 4 ℃.
For bead tethered pHrodo, 6 µL of pHrodo-conjugated antibody brought to 200 µL
TBST and added to 10 µL of either Dynabeads™ Protein G (Thermo Fisher Scientific,
10004D) or Protein A Agarose Resin (Gold Biotechnology, P-400-5). Beads and
antibody were incubated and rotated at room temperature for 10 minutes. Conjugated
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beads were washed 3 times with 200 µL TBST then stored in a final volume of 10 µL
TBST at 4℃.
3 µL pHrodo labeled antibody and 1 µL Hoechst 33342 trihydrochloride,
trihydrate (Thermo Fisher Scientific, H3570) was added to 70-80 % confluent HUVECs
plated on laminin coated dishes in 1 mL media and incubated at 37℃ for 10 minutes.
After 10 minutes, the cells were washed 3 times with 1 mL DPBS and then placed in 2
mL media. 10 z-stack images were taken for each condition, this marks time point 0
minutes. After images were taken of each group, cells were returned to 37℃ for 10
minutes and imaged again.

Microscopy
Images were taken on a Nikon Eclipse Ti inverted microscope equipped with a
CSU-X1 Yokogawa spinning disk field scanning confocal system and a Hamamatusu
EM-CCD digital camera. Cell culture images were captured using a Nikon Plan Apo 60x
NA 1.40 oil objective using Olympus type F immersion oil NA 1.518 (ThorLabs, MOIL30). Fish images were taken using either Nikon Apo LWD 20x NA 0.95 or Nikon Apo
LWD 40x NA 1.15 water objectives. For transmission electron microscopy images,
primary HUVEC of specified treatment were fixed in 2% glutaraldehyde, 2% PFA, 0.2 M
Cacodylate buffer and sent to Jennifer Bourne at the University of Colorado Anschutz
Medical Campus.
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Immunohistochemistry
2D cell culture was fixed in 4% paraformaldehyde in DPBS for 10 minutes. Cells
were then washed 3 times for 5 minutes in TBST and permeabilized in 0.1% Triton-X
100 for 10 minutes. Cells were then washed 3 times for 5 minutes and blocked for 1 hour
in 2% bovine serum albumin (BSA). Primary antibodies were applied at specified
dilutions in Key Resources Table (Appendix A) overnight. Cells were washed 3 times for
10 minutes in TBST and then moved to secondary for 2 hours at specified dilutions in
Key Resources Table. Cells were washed again 3 times for 15 minutes in TBST before
imaging.

Western Blot
Primary HUVEC culture was trypsinized and lysed using Ripa buffer (20 mM
Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1%
sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM
Na3VO4, 1 µg/mL leupeptin) containing 1x ProBlock™ Protease Inhibitor Cocktail -50,
Plus EDTA (GoldBio, GB-334-20). Total concentration of protein in lysate was
quantified using the Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific,
23225) measured at 562 nm and compared to a standard curve. 20-50 µg protein
was prepared in 0.52 M SDS, 1.2 mM bromothymol blue, 58.6% glycerol, 75 mM Tris
pH 6.8, and 0.17 M DTT. Samples were boiled for 10 minutes, then 35 µL was loaded
in a 7-12% SDS gel and run at 170 V. Protein was then transferred to Immun-Blot
PVDF Membrane (BioRad, 1620177) at 4℃, 100 V for 1 hour 10 minutes. Blots were
15

blocked in 2% milk for 1 hour, then put in primary antibody at specified
concentrations overnight. After 3 10-minute washes with TBST, secondary
antibodies at specified concentrations were applied for 4 hours. After 3 additional
TBST washes, blots were developed with ProSignal® Pico ECL Spray (Genesee
Scientific, 20-300S).

Pharmacological Treatment
DAPT (Sigma Aldrich, D5942) was applied to cells for 3 days at a final
concentration of 5 µM. Dynasore hydrate (Sigma Aldrich, D7693) was applied to cells
for 30 minutes at a final concentration of 100 µM. LY-411575 (Sigma Aldrich,
SML0506) was diluted in egg water to a final dilution of 2 µM from 30-48 hpf.
Latrunculin A (Sigma Aldrich, 428021-100UG) was applied to cells for 1 hour at a final
concentration of 5 µM. Cytochalasin B (Sigma Aldrich, C6762-5MG) was applied to
cells for 1 hour at a final concentration of 10 µM. Methyl-β-Cyclodextrin (Sigma
Aldrich, M7439-1G) was applied to cell for 10 minutes at a final concentration of 10
mM.

RNA-Sequencing
RNA collected from siRNA treated HUVEC was collected in triplicate and sent to
Novogene for RNA-sequencing. Sequence files received from Novogene were processed
using the Bioconductor package in R-Studio as described by Love et al. (2015) using
Homo Sapiens GRCh38 version 98 as a reference genome.
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Quantification and Statistical Analysis
Ectopic vessels were defined by a sprout emerging out of or separate from the
defined ISV and quantified in 48 hpf embryos expressing tg(kdrl:GFP). Number of
filopodia per ISV was defined by filopodial extensions (observed with zebrafish line
tg(fli:LifeAct-GFP)) emerging from a fully formed ISV that has connected with the
dorsal longitudinal anastomotic vessel. RT-PCR was quantified using the gel analysis
function in Fiji image analysis software (Schindelin et al., 2012). In sum, rectangular
sections were drawn around individual lanes in gray-scale, high-quality gel image using
the pathway Analyze > Gel > Select First Lane, Analyze > Gel > Select Next Lane. After
all lanes are selected, the pathway Analyze > Gel > Plot Lanes was used. The peaks of
each lane were then segmented using the Straight Line selection tool, and highlighted
with the Wand tool. Selection of the area inside the peak generates a Results window
with the area and percent of each peak. The percent value of each sample was divided by
the percent value of the control to obtain a relative density. Relative densities of the gene
of interest (e.g. Hey2) were divided by the relative density of the housekeeping gene
(GAPDH) to obtain a final adjusted density value.
Cellular uptake of pHrodo-labeled antibody was also quantified using Fiji image
analysis software. Stack files were z-stacked at maximum intensity, and each color
channel was adjusted so that the background was zero. Each individual cell was outlined
with the Freehand Selections tool. The color channels were then separated and any
background fluorescence (488 channel) was subtracted from the pHrodo fluorescent
intensity (561 channel) using pathway Process > Image Calculator. The Integrated
17

Density of pHrodo fluorescent intensity within each cell boundary was then recorded for
every cell at each time point. Each experiment was performed in duplicate. All statistical
analysis was performed in GraphPad Prism8.
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Chapter Three: Results
Loss of EHBP1 and EHD2 produces vascular defects in zebrafish
To investigate whether EHBP1 and EHD2 have a role in angiogenesis, we first
sought to characterize how the loss of EHBP1 or EHD2 affects intersomitic vessel (ISV)
development in Danio rerio (zebrafish). ISVs are used as a hallmark of normal blood
vessel patterning as in normal development, they form highly stereotyped chevron
shapes. During angiogenesis, the ISVs sprout from the dorsal aorta and migrate towards
the dorsal longitudinal anastomotic vessel roughly between 20-36 hours post fertilization
(hpf). In this vessel bed, specification between tip cell and stalk cell through the
Dll4/Notch1 signaling pathway must be tightly regulated and under normal signaling
dynamics will form highly stereotyped patterns. Aberrations in normal ISV growth, such
as ectopic vessels, are morphodynamically obvious and indicate a potential disruption to
the Notch signaling pathway.
A 4-guide KO approach (Wu et al. 2018) was employed targeting EHBP1 and
EHD2 in zebrafish to create F0 knockouts (KO) at these loci (Figure 4A). All injections
were done into a tg(kdrl:GFP)+/+ line, GFP under a vascular promoter, for visualization of
blood vessels. Due to multiple gene duplication events in teleosts, EHD2 has two
isoforms in zebrafish: EHD2a and EHD2b. While previous in situ hybridizations suggest
that EHD2b is the dominant isoform (Thisse and Thisse, 2007), each isoform was
targeted individually as well as in combination. Quantification of the proportion of
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Figure 4. Global deletion of EHBP1 and EHD2a/b produces vascular defects in
zebrafish. (A) Red dashed box denotes area of imaging. 4-guide knockout (KO) fish
were imaged on tg(kdrl:GFP)+/+ background at 48 hpf. Yellow arrows denote abnormal
vascular growth. Teal arrows point to spiny projections. (B) Quantification of the
proportion of 4-guide KO fish with ectopic ISVs. Ectopic was defined as a vessel
projection emerging from the ISV distinct from the central stalk. T-test analysis used
between EHBP1 and Scram. One-way ANOVA analysis between EHD2a, EHD2b,
EHD2a/b and Scram. Error bars represent SEM. n= number of fish quantified.
fish with ectopic ISVs in each condition revealed a significant increase in EHBP1
knockout fish (18.15%), as well as a significant increase in EHD2a/b knockout fish
(21.76%) compared to a scramble control (Figure 4B). These results suggest that EHBP1
and EHD2a/b are necessary for normal sprouting behaviors in endothelial cells (ECs).
Focusing on EHBP1, as this protein is less well characterized, we sought to
determine the endogenous expression of EHBP1 in zebrafish. However, antibodies that
detect EHBP1 in zebrafish are not available. To circumvent this, we fused a FLAG
epitope to the n-terminal domain of the endogenous EHBP1 locus using CRISPR/Cas9
targeting (Hoshijima et al. 2016) (Figure 5A). Staining for FLAG-EHBP1 endogenous
expression revealed that EHBP1 strongly localized to neuronal projections (Figure 5A).
To determine if EHBP1 was being expressed in ECs we dissociated embryos expressing
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Figure 5. Vascular excision of EHBP1 produces vascular defects in zebrafish. (A)
Staining against FLAG epitope in various stages of development highlighting expression
in the neural tube (NT) in indicated genotypes. (B) Ex vivo validation of expression of
FLAG-EHBP1 in endothelial cells. Yellow arrows denote areas of FLAG positivity. (C)
Confirmation of in frame lox site incorporation into F1 generation EHBP1 floxed fish.
Predicted sequence shown in first row, sequenced F1 fish shown in second row. Sanger
sequencing peaks of small region in c-terminal lox site highlighted to the right.
(D) Representative images of ISVs in indicated genotypes. Yellow arrows denote
abnormal vascular growth. (E) Quantification of proportion of fish with ectopic ISVs. Ttest analysis between groups. Error bars represent SEM. n= number of fish quantified.
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both FLAG-EHBP1 and a GFP-endothelial reporter at 48 hours post fertilization (hpf)
and plated individual ECs on a dish. We found there was indeed EHBP1 expression in
ECs at this time point (Figure 5B). EHD2b detected using in situ hybridization by Thisse
and Thisse (2007) demonstrated a similar expression pattern to EHBP1 along neuronal
projections.
Given the potentially confounding effects of performing a global knockout, a
floxed EHBP1 transgenic line was also created using CRISPR mediated recombination.
Validation of the successful incorporation of these lox sites into an F1 generation fish is
shown in Figure 5C. In line with our previous observations, excision of the floxed allele
exclusively in blood vessels using a kdrl promoter [EHBP1lox/lox; tg(kdrl:GFP)+/+ ;
tg(kdrl:Cre)+/+] also showed a significant increase (12.56%) in the proportion of fish with
ectopic ISVs (Figure 5D,E). This suggests that the blood vessel aberrations in EHBP1
and EHD2a/b knockout lines are not due to a confounding effect of global gene deletion.
Together, the global and vascular specific knockouts suggest that EHBP1 and EHD2a/b
mediate endothelial sprouting behaviors and are required for normal angiogenesis.

EHBP1 and EHD2 phenocopy Notch loss of function
We next sought to characterize the EHBP1 and EHD2a/b vascular abnormalities
in the context of Notch activity, as loss of Notch signaling has been previously shown to
promote hypersprouting (Therapontos and Vargesson 2010). As a reference, the
tg(fli:LifeAct-GFP)+/+ line which overexpresses a GFP tagged F-actin in the vasculature
was treated with 2 µM of the 𝛾-secretase inhibitor LY-411575 (Figure 6). Treatment
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with this small molecule 𝛾-secretase inhibitor prevents cleavage of the NICD at the S3
site and subsequent translocation of the NICD to the nucleus. In this
Notch loss of function control, there was a significant increase in the number of ectopic
sprouts per ISV in comparison with a DMSO treated control group, phenocopying the
increase in ectopic sprouting observed in EHBP1 and EHD2 KOs and supporting the
potential role of EHBP1 and EHD2 in Notch signaling (Figure 6B). We also observed a
significant increase in the number of filopodia per ISV in the LY-411575 treated
fish(Figure 6A,C). Given that spiny, filopodial projections are characteristic of a tipidentifying cell, as would occur in a low-Notch signaling environment, we used this as
another measurement of Notch loss of function. The 4-guide KO injections were thus
repeated using the F-Actin overexpression line (Figure 7A).

Figure 6. 𝜸-secretase inhibitor produces vascular defects in zebrafish. (A) ISVs of
fish treated with either DMSO or 2 µM LY-411575 on tg(fli:LifeAct)+/+ background.
Yellow arrows point to ectopic sprouts. Teal arrows point to filopodial projections. (B)
Number of ectopic ISVs per fish between indicated groups. Error bars represent SEM.
(C) Number of ISV filopodial extensions between indicated groups. T-test analysis
performed between groups. Error bars represent SD n=number of fish.
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Figure 7. Notch loss of function in EHBP1 and EHD2 KO zebrafish. (A)
Representative images of 4-guide KO of EHBP1 and EHD2 on tg(fli:LifeAct-GFP)+/+
background. Yellow arrows point to ectopic sprouts. (B) Number of ISV filopodial
extensions among indicated groups. One-way ANOVA analysis between groups. Error
bars represent SD. (C) Relative expression of Hey2 transcript in 48hpf 4-guide KO fish
compared to GAPDH control across indicated groups. One-way ANOVA analysis
between groups. Error bars represent SEM. n=number of fish, ns=nonsignificant.

The number of filopodia per ISV were quantified and showed no significant
difference in the filopodia per ISV in the 4-guide KO fish compared to a scramble control
(Figure 7B). These 4-guide KO fish were collected at 48 hpf and their RNA was
extracted and converted to cDNA library. The expression of
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downstream Notch1 target Hey2, a marker of S3 cleavage and downstream Notch
activation, was monitored in each KO sample and compared to a GAPDH control. We
found a significant decrease in the expression of Hey2 in EHBP1, EHD2b, and EHD2a/b
KO fish in comparison with the scramble control (Figure 7C), further evidence of a
Notch loss of function in the absence of EHBP1 and EHD2.
In canonical tip/stalk cell specification, tip cells exhibit elevated Dll4 levels which
act to activate lateral inhibition through Notch activation in the trailing stalk cells (Figure
1). Given the Notch loss of function phenotype in EHBP1 and EHD2a/b KO fish, we
hypothesized that these proteins may influence hierarchical tip/stalk cell positioning. In
order to do this, GFP tagged 5xUAS constructs of the human orthologs of EHBP1 and
EHD2 were constructed. It should be noted that the zebrafish EHBP1 shares a 72.4%
homology to its human ortholog; zebrafish EHD2a and EHD2b share a 69.3% and 81.9%
homology respectively to their human ortholog. Therefore, we expect the human
orthologs to be representative of the zebrafish orthologs and behave similarly. We
predicted that if EHBP1 or EHD2 did not affect Notch activation there would be a largely
equal EC contribution in tip or stalk cell positions.
Confirming this, we injected a control tg(5xuas:LifeAct-GFP) construct and
observed mosaic integration with an even 50/50 distribution between tip and stalk ECs in
growing ISVs at 24 hpf (Figure 8). However, ECs expressing GFP-EHD2
(tg(5xUAS:GFP-EHD2)) demonstrated a significant bias toward the tip cell position with
76.9% of ISVs exhibiting EHD2-overexpressing ECs in the tip position (Figure 8)
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Similarly, GFP-EHBP1-expressing ECs showed a 61.5% bias to the tip cell position in
ISVs at 24 hpf (Figure 8). These results support the role of EHBP1 and EHD2 in Notch

Figure 8. EHBP1 and EHD2 preferentially express in tip cells during angiogenesis.
Representative images of GFP-EHD2, GFP-EHBP1, and LifeAct-GFP overexpression
constructs in growing ISVs at 24 hpf. Vasculature marked by Tg(kdrl:mCherry) (Red).
Quantification of the proportion of expressing endothelial cells in either the tip (T, blue)
or stalk (S, red) cell position in the growing vascular sprouts shown to the right. T-test
analysis between groups.
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activation, suggesting that EHBP1 and EHD2 may play a role in tip cell-related signaling
and support the spatiotemporal role of EHBP1 and EHD2 in Notch activation in tip cellrelated signaling.

EHBP1 and EHD2 organize around membranous Dll4 independent of clathrin
Given the effect of EHBP1 and EHD2 on Notch activation and tip cell preference
shown thus far in vivo, we next investigated the precise cellular mechanism through
which EHBP1 and EHD2 are acting on Dll4/Notch signaling. We hypothesized that
EHBP1 and EHD2 were involved in Dll4 endocytosis. Literature to date on Dll4
endocytosis is inconclusive in identifying its endocytic machinery. In the same vein, there
are few papers on EHBP1 in relation to endocytosis and even fewer on EHBP1 and
EHD2 in combination. They have been shown to be involved in both clathrin-dependent
and independent endocytic trafficking pathways. Thus, we first looked to a 2003 article
by Guilherme et al. which identified EHBP1 and EHD2 in facilitating the clathrin
mediated endocytosis of Transferrin and Glut4 through tethering to the actin
cytoskeleton.
To address this, we chose to focus only on the extracellular pool of Dll4 present
on the membrane and thus available for Notch binding and endocytosis using a pHluorinDll4 construct. The pH sensitive GFP variant pHluorin fluoresces on the surface of the
cell at a neutral pH but is quenched when internalized into low pH acidic vesicles (Figure
9A, Sankaranarayanan et al. 2000). Therefore, overexpression of the pHluorin-Dll4
construct in cell culture shows only the membrane-presenting pool of Dll4. An additional
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Figure 9. EHBP1 and EHD2 organize around Dll4 independent of clathrin. (A)
Schematic of pH-dependent function of GFP variant pHluorin tag. PHluorin fluoresces on
the membrane at neutral pH, but is quenched when internalized into acidic endosomes.
(B) EHBP1 localizes around sites of pHluorin-Dll4 independent of clathrin. (C) EHD2
localizes around sites of pHluorin-Dll4 independent of clathrin. Boxed are magnified
section on right. Yellow arrows show areas of colocalization.
consideration we took into account is that the cellular expression of Dll4 in 2D cell
culture is highly mosaic. In order to both stimulate Dll4 expression and homogenize it in
a single dish, all cells were plated onto laminin coated dishes, an integrin that stimulates
Dll4 expression (Estrach et al 2011).
Co-expression of pHluorin-Dll4 and tagRFP-EHBP1 in HUVEC showed that
EHBP1 clustered around sites of membranous Dll4 (Figure 9B). Likewise, Co-expression
of pHluorin-Dll4 and tagRFP-EHD2 showed that EHD2 formed clusters surrounding
Dll4 puncta on the membrane (Figure 9C). These results support the potential role of
EHBP1 and EHD2 in Dll4 endocytosis. However, clathrin was largely absent at these
28

sites (Figure 9B,C). Instead, the clathrin expression was diffuse and non-specific,
indicating that Dll4 is potentially endocytosed through a clathrin-independent pathway.
Emerald-clathrin and either tagRFP-EHBP1 or tagRFP-EHD2 were co-expressed
in HUVEC and stained for F-actin (Figure 10 A,B). We observed that while pHluorinDll4 puncta localized to EHBP1 and EHD2 clustered at sites of large F-actin bundles as
would be necessary to facilitate a coordinated endocytic event, clathrin was also absent
from these sites (Figure 10 A-D). Cells were then treated with one of two actin inhibitors:
chytochalasin B or latrunculin A. Cytochalasin B works by blocking de-novo actin
polymerization; Latrunculin A works by actively degrading existing actin fibers as well
as preventing de novo synthesis. In cells with either inhibitor, localization of EHBP1 and
EHD2 became diffuse and non-specific (Figure 10 E,F). At select sites were actin
junctions remained, there was a slight although noticeably blunted localization of EHBP1
and EHD2. Together, these results suggest that EHBP1 and EHD2 may act in the
clathrin-independent endocytosis of Dll4 that is dependent on tethering to the actin
cytoskeleton to function.

Localization of EHBP1 and EHD2 to Dll4 is dependent on Caveolin-1
Given the evidence of EHBP1 and EHD2 coordinating actin tethering to
membranous Dll4 independent of clathrin, we turned next to the potential that EHBP1
and EHD2 are coordinating Dll4 endocytosis through caveolin endocytosis. EHD2 has
previously been shown to act as dynamin-like ATPase driving the scission of caveolar
endocytic pits from the membrane, although this role has not been linked to Dll4,
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Figure 10. EHBP1 and EHD2 organize around Dll4 dependent on actin. (A,B)
EHBP1 and EHD2 localized to sites of F-actin bundling independent of clathrin. (C,D)
EHBP1 and EHD2 cluster around Dll4 puncta at sites of F-actin bundling. (E,F) Actin
inhibitors Cytochalasin B and Latrunculin A disrupt EHBP1 and EHD2 localization.
Boxed are magnified section on right. Yellow arrows show areas of colocalization.
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EHBP1, or actin-tethering (Morén et al. 2012). TagRFP-EHBP1 and caveolin1 both
formed around clusters of pHluorin-Dll4 on the membrane (Figure 11A). Equally,
tagRFP-EHD2 and caveolin 1 also formed around pHluorin-Dll4 on the membrane in
canonical clusters of rosettes characteristic of caveolae (Figure 11B).
To determine if this colocalization suggested that Dll4 is in fact endocytosed
through a calthrin-independent, caveolin-mediated endocytosis, we used the cholesterol
inhibitor Methyl-β-cyclodextrin (MβCD) which disrupts caveolae. Accordingly,
caveolin-1 in cells treated with MβC failed to form canonical rosettes and instead was
structurally indistinct throughout the cell (Figure 11C,D). EHBP1 and EHD2 also lost
much of the structural definition shown in the previous figures and failed to organize
around Dll4 (Figure 11C,D). These results suggest that EHBP1 and EHD2 facilitate
endocytosis of Dll4 via caveolin-mediate endocytosis.

EHBP1, EHD2, and caveolin localize to adherens junctions in 3D sprouts
Despite homogenization of Dll4 in 2D HUVEC assays, the localization of
proteins may not accurately reflect the localization of the same proteins in a 3D vascular
sprout. We therefore employed a 3D sprouting assay wherein beads coated with HUVEC
are embedded into a matrix and form sprouts to assess the expression of EHBP1 and
EHD2 relative to Dll4 at adherens junctions (Figure 12A). As in 2D cell culture, tagRFPEHBP1 colocalized strongly with actin in 3D sprouts, supporting the role of EHBP1 to
tether actin through its CH domain (Figure 12B). This localization was severely disrupted
in sprouts treated with EHD2si, supporting the cooperative nature of EHBP1 and EHD2
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Figure 11 EHBP1 and EHD2 organize around Dll4 dependent on caveolin. (A,B)
EHBP1 and EHD2 localize to surface pHluorin-Dll4 and colocalize with caveolin-1. (C)
EHBP1 and (D) EHD2 fail to localize to Dll4 when treated with MβCD (cholesterol
inhibitor). Boxed are magnified section on right. Yellow arrows show areas of
colocalization.
working in concert at the Dll4 caveolar endocytic pit at the junction between tip and stalk
cell (Figure 12C). It is possible that EHD2 is required for EHBP1 to tether actin through
its CH domain, potentially through some modification of CH domain availability.
Alternatively, EHD2 may not be required for EHBP1 to tether actin, but rather signals
EHBP1 to recruit it to an endocytic pit.
TagRFP-EHBP1 also displayed a strong affinity to the adherens junction in the
3D sprout, which was severely disrupted in EHD2si treated cells (Figure 12D,E).
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Figure 12. EHBP1, EHD2, and Caveolin localize to adherens junctions in 3D
vascular sprouts. (A)Schematic of 3-dimensional sprout growth in fibrin bead assay
(FBA). (B,C) Representative EC sprout stained for actin expressing tagRFP-EHBP1,
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treated with indicated siRNA. (D,E) Representative EC sprout stained for VE-cadherin
(VE-cad) expressing tagRFP-EHBP1, treated with indicated siRNA. (F,G) Representative
EC sprout stained for VE-cadherin (VE-cad) expressing tagRFP-EHD2, treated with
indicated siRNA. (H) Dll4 and caveolin-1 colocalize at adherens junction in P6 mouse
retinal blood vessels. Boxed are magnified section on right. Yellow arrows show areas of
colocalization. Teal arrows show areas of mislocalization.

Equally, tagRFP-EHD2 strongly localized to adherens junctions and this localization was
disrupted in EHBP1si treated cells (Figure 12F,G). This localization supports the EHBP1
and EHD2 gain of function assay (Figure 8) to conclude that EHBP1 and EHD2 are
present at sites of Dll4/Notch1 binding and therefore ready and able to trans-endocytose
the Dll4/Notch1complex at the adherens junction between tip and stalk cell. The
dependence of EHBP1 and EHD2 on each other to localize to these sites paint a picture
of interdependent proteins available, and required for, tethering to the cytoskeleton at
adherens junctions. In P6 mouse eyes, caveolin strongly colocalized to Dll4 at adherens
junctions (Figure 12H). Taken together, these results support the role of EHBP1 and
EHD2 acting with caveolin to tether Dll4 endocytic pits to the actin cytoskeleton.

Loss of EHBP1 and EHD2 blunts Dll4 endocytosis and caveolar integrity
With evidence of EHBP1 and EHD2 working together to tether caveolin-mediated
endocytosis of Dll4 to the cytoskeleton, we next sought to characterize any Dll4
endocytic defects resulting from loss of EHBP1 or EHD2 in cell culture. In order to do
this, an anti-Dll4 antibody was linked to pHrodo™ iFL Red STP Ester and used in a
pulse-chase internalization assay. Similar to pHluorin, pHrodo™ is a pH sensitive probe.
However, in contrast to pHluorin, pHrodo™ is non-fluorescent on the membrane and
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increases fluorescent intensity with decreasing endosomal pH (Figure 13A, Kamen et al.
2019). In an endosome targeted for lysosomal degradation, the intensity of the pHrodo
will reach a peak and then be quenched once the tethered antibody and probe are
degraded by the lysosome. This property allows us to track how internalization of a
tagged antibody bound to Dll4 on the membrane is impacted by loss of EHBP1 and
EHD2. As a control, a goat-anti-mouse IgG was also linked to the pHrodo tag.
We observed that pHrodo™ pulse-chase with a non-specific antibody does result
in a low-level internalization over time (Figure 13B). In scramble treated cells in which
the pHrodo™ linked anti-Dll4 antibody was used, there was a sharp peak in fluorescent
intensity at the 10-minute time point. This suggests that antibody-bound Dll4 is rapidly
internalized and trafficked to the lysosome. Notably, this internalization event is absent in
EHBP1si, EHD2si, and combination EHBP1/EHD2si treated cells suggesting that
EHBP1 and EHD2 are required for proper internalization of Dll4 to occur (Figure 13B).
This absence of internalization is consistent in cells treated with the dynamin inhibitor
Dynasore and cholesterol inhibitor MβCD which disrupts caveolae, suggesting that it is a
caveolin endocytic defect (Figure 13C). As EHD2 is functionally similar to dynamin,
these results also suggest that the endocytic defect caused by loss of EHD2 may be due to
the failure of scission of the Dll4 endocytic pit from the membrane. To validate that this
disruption of antibody bound Dll4 endocytosis was directly related to its role in Notch
signaling, we then pHrodo™ labelled a recombinant soluble NECD protein which will
bind and transendocytose Dll4. Because this recombinant NECD has no tension or force
to apply to Dll4 as a native NECD bound to the cell would, we functionalized this
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Figure 13. Endocytosis of Dll4 and NECD are dependent on EHBP1 and EHD2. (A)
Schematic of pHrodo labeled Dll4 antibody. PHrodo gains fluorescent intensity with
increasing endosomal pH, thus used as a metric of endocytosis. (B,C) Relative
internalization of pHrodo-Dll4 pulse-chase over time between indicated siRNA groups.
IgG was used a non-specific internalization control. Dynasore is pan-endocytosis
inhibitor. MβCD is a cholesterol specific inhibitor that disrupts caveolin. (D) Schematic
recombinant Notch intracellular domain (NECD) functionalized to microbead and labeled
with pHrodo. (E,F) Relative internalization of NECD pulse-chase over time between
indicated siRNA groups. Significance between scramble group and other groups listed in
order of figure legend. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001. ns=nonsignificant.
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labelled protein to an agarose bead (Figure 13D). The kinetics of internalization were
different in scramble treated cells compared to the Dll4-antibody internalization (Figure
13E). However, this baseline internalization was also significantly impaired by treatment
with EHBP1si, EHD2si, and EHBP1/EHD2si in combination (Figure 13E). The same
internalization defect was also seen in Dll4si, Jag1si, and dual Dll4/Jag1si, again linking
this defect directly to Dll4 endocytosis and the Notch signaling pathway (Figure 13F).
We considered that the disruptions in siRNA treated cells to Dll4 endocytosis may
be indicative not of an endocytic defect, but rather a reduction of Dll4 due to a negative
feedback loop. However, we observed that in whole cell lysate samples of EHBP1si and
EHD2si treated cells with DAPT and dynasore controls that protein levels of Dll4
remained constant (Figure 14A,B). Therefore, the reduced internalization of Dll4 is a
direct result of loss of EHBP1 and EHD2, supporting their role as endocytic mediators of
Dll4/Notch1 transendocytosis in endothelial cells.
In order to visualize this endocytic impairment in the absence of EHBP1 and
EHD2, we submitted treated samples to the University of Colorado Anschutz Medical
campus for TEM imaging. We observed an increased number of small endocytic caveolar
vacuoles near the plasma membrane, but failing to form large structures or fuse with the
membrane (Figure 14C). This is consistent with TEM observations of EHD2si treated
cells previously (Morén et al. 2012). We propose that this is a result of caveola unable to
be stabilized at the plasma membrane by the structural machinery of EHBP1
and EHD2. In the absence of the structural support and mechanical force generated by
EHBP1 and EHD2, Dll4 is unable to expose the S2 cleavage site of Notch1.
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Figure 14. Loss of EHBP1 and EHD2 result in loss of caveolar structure. (A,B)
Western blot of Dll4 levels across indicated treatment groups. (C) TEM analysis of
caveolar structure in ECs in across indicated siRNA treatments. White inset boxes show
area of magnification.
RNA-seq analysis of EHBP1 deficient cells
The purpose of our RNA-sequencing analysis was two-fold. First, comprehensive
knowledge of EHBP1 is almost absent from the literature. Second, the evidence we have
gathered thus far of the role of EHBP1 and EHD2 in caveolin-mediated endocytosis has
broad reaching implications for the potential cell-wide roles of these two proteins. We
therefore sent 3 replicates each of scramble siRNA treated cells and EHBP1si treated
cells to Novogene for sequencing. Prior to sending the samples, confirmation of KD
efficiency was validated by western blot (Figure 15A).
In the EHBP1si treated group, there were only 99 significantly differentially
regulated genes compared to the control (Appendix B). A volcano plot shows the logfold-change of gene expression between the scramble and EHBP1si treated ECs, with
upregulation presented above the line and downregulation presented below the line
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(Figure 15B). Of these 99 differentially regulated genes, approximately 45% either
contained EGF repeats, analogous to Dll4 and Notch, or were indirectly related to EGFcontaining protein signaling processes (Figure 15B, C). Further analysis revealed that 8
of the 99 genes were directly related to caveolin endocytosis (Figure 15B, D) and 4 of the
99 genes were actin remodeling genes (Figure 15B, E). This suggests that EHBP1’s role
in regulating caveolin-mediated endocytosis may not be specific to Dll4 but can
accommodate a variety of cargo.
To see if this trend translated to an increased consequence to angiogenic
signaling, we grouped the differentially regulated genes by gene ontology (Figure 16). 8
genes were directly attributed to either angiogenesis, blood vessel development, or
response to hypoxia (Figure 16A). Another 11 genes were more broadly attributed to the
trafficking ontologies SNARE binding, G protein-coupled receptor binding, exocyst, and
MAPK cascade (Figure 16B). Beyond these, all differentially regulated gene ontologies
are represented in a bar plot and show a dramatic impact on cellular processes as a whole
(Figure. 16C).
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Figure 15. RNA-Seq analysis of loss of EHBP1 in HUVEC. (A) Confirmation of
knockdown efficiency of EHBP1 siRNA replicates. (B) Volcano plot distribution of all
differentially regulated genes in EHBP1si condition compared to control. Dots above the
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line represent upregulation; dots below the line represent downregulation. Dark green
dots represent significantly differentially regulated genes. Highlighted points are relevant
to angiogenic signaling. (C) Number of significantly different transcripts that contain
EGF repeat motifs, are (D) directly related to caveolin-mediated endocytosis or (E)
directly related to actin remodeling.
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Figure 16. Gene ontology analysis of differentially regulated genes reveals cell-wide
signaling disruptions. (A) Significantly differentially regulated genes related to
angiogenesis. (B) Significantly differentially regulated genes related to endo- or
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exocytosis. (C) All gene ontology groupings of significantly differentially regulated
genes. Bars shown in red were upregulated as a group. Bars shown in blue were
downregulated as a group.
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Chapter 4: Conclusions
The endocytosis of Delta ligands, particularly Dll4, to regulate Notch signaling in
endothelial cells has previously remained uncharacterized. We have shown here for the
first time that two proteins, EHBP1 and EHD2, act to regulate Notch signaling through
the transendocytosis of the Dll4/Notch1 complex by caveolin-mediated endocytosis. This
is the first characterization of Dll4 as being endocytosed by caveolin-mediated
endocytosis in endothelial cells, and this knowledge can be used to further studies of
Dll4/Notch1 endocytosis and signaling. Furthermore, this is the first report to show
EHBP1 and EHD2 acting together to regulate clathrin-independent endocytosis through
tethering to the actin cytoskeleton.
Loss of either EHBP1 or EHD2 in zebrafish produced a significant increase in
vascular defects characteristic of Notch pathway inhibition. Normally smoothened,
established ISVs with a stalk cell identity became branching, spiny, migratory cells
characteristic of increased tip cell identity. This aberration to the Notch pathway was
confirmed by RT-PCR, which revealed a significant downregulation of the downstream
Notch target Hey2 in EHBP1 and EHD2 KOs. Overexpression of vascular driven EHBP1
and EHD2 injected into zebrafish showed a strong preference toward the tip cell position,
as would be expected by proteins regulating the endocytosis of Dll4. While previous
literature suggested that EHBP1 and EHD2 worked together in clathrin mediated
endocytosis, we show here that EHBP1 and EHD2 regulate Dll4 endocytosis independent
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of clathrin. Clathrin is largely absent from sites of EHBP1, EHD2, and actin. However,
EHBP1 and EHD2 still localized to junctions of actin containing Dll4. This suggested
that some other endocytic mechanism was at play. Clusters of EHBP1 and EHD2
colocalized strongly with caveolin-1 around Dll4 on the membrane. This localization was
disrupted in cells treated with caveolin 1 inhibitor MβC, suggesting that EHD2 and
EHBP1 are in fact binding to caveolin 1. The functional localization of these proteins was
validated in cells with 3D structure, showing that EHBP1 and EHD2 localized to each
other at actin bundles and adherens junctions and are dependent on one another to
maintain this localization. In P6 mouse eyes stained for Dll4 and caveolin 1 there was a
strong colocalization at adherens junctions.
We validated the functional requisite of EHBP1 and EHD2 to assist Dll4 in
caveolin-mediated endocytosis through pulse chase internalization assays. In cells lacking
EHBP1 or EHD2, a pHrodo labeled Dll4 antibody failed to internalize with the same
dynamics as scramble siRNA treated cells. This failure to internalize was also observed
in a pulse chase internalization assay with a bead-functionalized recombinant Notch
extracellular domain. These results suggest that internalization of the Dll4/NECD
complex is impaired in the absence of EHBP1 and EHD2. This failure to internalize was
not due to a feedback loop downregulation of Dll4. In line with previous reports, TEM
revealed that loss of EHBP1 and EHD2 compromised the structural integrity of the
caveolar pit.
Taken together, we propose a model wherein EHD2 oligomerizes around the neck
of the endocytic vesicle containing Dll4 bound to the NECD by binding to caveolin 1
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(Figure 17). The EH domain of EHD2 also binds to the NPF motifs of EHBP1. EHBP1 is
tethered to the actin cytoskeleton, generating the force necessary to expose the S2
cleavage site of Notch and allow for effective Notch signaling (Figure 17). In the absence
of EHBP1, the caveolar pit will be unable to tether to the actin cytoskeleton. In this event,
the caveolar pit will lose structure provided by the actin support and be unable to
generate the force necessary for Dll4/NECD transendocytosis. In the absence of EHD2,
the caveolar pit will lose the ability to perform scission from the membrane in addition to
losing the bridge to the actin cytoskeleton through EHBP1.
The impairment of caveolin-mediated endocytosis in the absence of EHBP1 and
EHD2 was also shown here to have broad reaching implications for endo- and exocytosis
as a whole through the RNA sequencing analysis of EHBP1 siRNA treated endothelial
cells. The exocyst complex, MAPK cascade, SNARE binding, and G protein coupled
receptor binding are just some of the cellular signaling pathways affected by the loss of
EHBP1 in the cell.
One future experiment should employ atomic force microscopy on Dll4 and
Notch1 in both scramble treated, EHBP1si treated, and EHD2si treated endothelial cells
to validate the force requirement of the EHBP1-EHD2 complex on exposing the S2
cleavage domain of Notch1. To further this aim of validating exposure of the S2 cleavage
site on Notch1 we propose to use, and have begun to construct, a recombinant Notch1
protein tagged at the n-terminus with a Flag epitope and at the c-terminus with an HA
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Figure 17. Model of EHBP1 and EHD2 generating force on caveolar pit. (A) Dll4
binds NECD in the budding caveolin pit. (B,C) EHD2 binds caveolin and oligomerizes
around the neck of the endocytic pit. EHBP1 binds to EHD2 and tethers the actin
skeleton through the CH domain. This generates the force necessary to expose the S2
cleavage site on Notch.

epitope. This would allow us to stain against both epitopes to observe whether cleavage
of the S2 site has occurred.
If an insufficient force were applied, as we propose is occurring in the absence of
EHBP1 and EHD2, staining against both epitopes should decorate the cell membrane
where the intact Notch1 ligand remains. If a sufficient force were applied, staining for the
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HA epitope should decorate the nucleus, where the cleaved NICD has traveled; the Flag
epitope should decorate vesicles containing Dll4.
If, in fact, this direct demonstration of force holds showing that EHBP1 and
EHD2 provide a necessary and sufficient force to expose the S2 cleavage domain of
Notch1, this would have interesting implications for the opposing signaling effects
between Dll4 and Jag1 after binding Notch1. As stated in the introduction, Dll4 and Jag1
are almost identical in domain composition, bind Notch1 at the same site, yet have
opposite signaling consequences; the reasons for this signaling discrepancy are vague and
incomplete.
Is it possible that the real signaling discrepancy between Dll4 and Jag1 are
produced by an insufficient force after Jag1/Notch1 binding? In this case, Jag1 would
occupy Notch1 EGF binding sites, effectively blocking binding by Dll4. But, without the
force supplied by EHBP1 and EHD2, Jag1 would be unable to expose the S2 cleavage
site and would therefore blunt Notch signaling. All experiments shown here could be
repeated with Jag1 instead of Dll4 to demonstrate this possibility.
Overall, the data shown here demonstrate for the first time in endothelial cells that
Dll4 is endocytosed via caveolin-mediated endocytosis using the proteins EHBP1 and
EHD2. This is important as it contradicts the clathrin-mediated endocytic mechanism of
other Delta-like ligands in other tissue types described in the literature and expands the
field’s knowledge of a signaling pathway absolutely critical to angiogenesis.
Furthermore, our characterization of the broad trafficking role of EHBP1 in endothelial
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cells suggests a vital function of a previously poorly characterized protein which can be
explored more deeply in future studies.
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Appendix A
Reagent Type
(species) or
Resource
Antibody
Antibody
Antibody
Antibody
Antibody
Antibody
Antibody

Antibody
Antibody
Antibody
Antibody
Antibody

Antibody

Antibody

Designation

Source or
Reference

Identifiers

Additional Information

Clathrin Heavy
Chain Monoclonal
Antibody (Mouse)
Caveolin 1
Polyclonal Antibody
(Rabbit)
Dll4 Polyclonal
Antibody (Goat)
Dll4 Polyclonal
Antibody (Rabbit)
Dll4 Polyclonal
Antibody (Mouse)
EHBP1 Polyclonal
Antibody (Rabbit)
EHD2 Polyclonal
Antibody (Rabbit)

Thermo Fisher
Scientific

MA1-065

Immunohistochemistry:
1/1000 dilution

Thermo Fisher
Scientific

PA1-064

Immunohistochemistry:
1/2000 dilution

Thermo Fisher
Scientific
abcam

PA5-46974

Immunohistochemistry:
1/1000 dilution
Immunoblotting:
1/500 dilution

Thermo Fisher
Scientific
Thermo Fisher
Scientific
Thermo Fisher
Scientific

PA5-46974

Recombinant Antialpha Tubulin
antibody (Rabbit)
Monoclonal Anti-⍺Tubulin antibody
(Mouse)
VE-cadherin
polyclonal antibody

Abcam

DYKDDDDK
Tag polyclonal
antibody
Donkey anti-Mouse
IgG (H+L) Highly
Cross-Absorbed
Secondary
Antibody, Alexa
Fluor 647
Goat anti-Rabbit
IgG (H+L) Highly
Cross-Absorbed
Secondary
Antibody, Alexa
Fluor Plus 647
Chicken anti-Rabbit
IgG (H+L) CrossAbsorbed Secondary
Antibody, Alexa
Fluor 647

ab7280

PA5-57282
PA5-61497

ab52866

Immunohistochemistry:
1/500 Dilution
Immunohistochemistry:
1/1000 dilution
Immunoblotting: 1/500
dilution
Immunoblotting:
1/5000 dilution

Sigma Aldrich

T9026-.2ML

Immunoblotting: 1/5000
dilution

Enzo Life
Sciences

ALX-210232-C100

Immunostaining: 1/200

Thermo Fisher
Scientific

PA1-984B

Immunostaining: 1/100
dilution

Thermo Fisher
Scientific

A-31571

Immunostaining: 1/1000
dilution

Thermo Fisher
Scientific

A32733

Immunostaining: 1/1000
dilution

Thermo Fisher
Scientific

A-21443

Immunostaining: 1/1000
dilution
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Antibody

Goat anti-Mouse
IgG (H+L)
Secondary
Antibody, HRP
Goat Anti-Rabbit
IgG (HL), HRPLinked Whole Ab
Hoechst 33342,
trihydrochloride,
trihydrate
Alexa Fluor™ 647
Phalloidin
Recombinant
Human Notch-1 Fc
Chimera
Cas9 protein with
NLS, high
concentration
Cytochalasin B

Thermo Fisher
Scientific

31430

Immunoblotting: 1/5000
dilution

Genesee
Scientific

20-303

Immunoblotting: 1/5000

Thermo Fisher
Scientific

H3570

1/1000 dilution cell
culture

Thermo Fisher
Scientific
R&D Systems

A22287

1/500 dilution cell culture

PNA Bio

CP02

Sigma
Aldrich

C67625MG

Dimethyl sulfoxide
≥99.5%, Ultra Pure
Grade
LY-411575

VWR Life
Science

97063-136

Sigma Aldrich

SML05065MG

2 µM final concentration

Latrunculin A

Sigma Aldrich

428021100UG

5 µM final concentration

Chemical
compound
Chemical
compound

Methyl-βcyclodextrin
pHrodo™ iFL Red
STP Ester (aminereactive)

Sigma Aldrich

M7439-1G

10 mM final dilution

Thermo Fisher
Scientific

P36010

Chemical
compound

DAPT

Sigma Aldrich

D5942-5MG

5 µM final concentration

Chemical
compound

Dynasore hydrate

Sigma Aldrich

D7693-5MG

100 µM final
concentration

Chemical
compound
Commercial
assay or kit

Phenol Red

VWR

470301-974

0.1% final dilution in
water

MEGAscript™ T3
Transcription Kit

Thermo Fisher
Scientific

AM1338

Commercial
assay or kit

HiScribe™ SP6
RNA Synthesis Kit

New England
BioLabs

Antibody
Cellular Dye
Cellular Dye
Recombinant
Protein
Chemical
compound
Chemical
compound
Chemical
compound
Chemical
compound
Chemical
compound
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P46531

E2070S

Commercial
assay or kit

High Capacity
cDNA Reverse
Transcription Kit
Dynabeads™
Protein G for
Immunoprecipitation
Protein A Agarose
Resin

Thermo Fisher
Scientific

4368814

Thermo Fisher
Scientific

10004D

Gold
Biotechnology

P-400-5

Other

Poly-D-Lysine

Thermo Fisher
Scientific

A3890401

Other

Laminin Mouse
Protein, Natural

Thermo Fisher
Scientific

23017015

Other
Other
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Appendix B
baseMean

log2Fold
Change

ENSG00000089723

22.1014999

-4.63E+00

ENSG00000183840

27.3967476

-3.15E+00

ENSG00000157045

171.041544

ENSG00000115504

lfcSE

stat

pvalue

padj

symbol

NA

OTUB2
1.13612207

-4.0720217

4.66E-05

0.85943631

-3.6656858

0.00024668

3.52E-02

GPR39

-1.99E+00

0.36389978

-5.4718281

4.45E-08

2.17E-05

NTAN1

473.845438

-1.73E+00

0.22589519

-7.6578629

1.89E-14

4.80E-11

EHBP1

ENSG00000081041

242.551212

-1.59E+00

0.27410654

-5.7860868

7.20E-09

5.38E-06

CXCL2

ENSG00000169429

764.532758

-1.55E+00

0.1774785

-8.7351553

2.43E-18

1.03E-14

CXCL8

ENSG00000163131

182.37218

-1.54E+00

0.34081567

-4.5207608

6.16E-06

1.78E-03

CTSS

ENSG00000163739

1040.71362

-1.46E+00

0.22843278

-6.385674

1.71E-10

1.97E-07

CXCL1

ENSG00000010319

632.589134

-1.22E+00

0.2171759

-5.6369928

1.73E-08

1.14E-05

SEMA3G

ENSG00000205403

451.260567

-1.18E+00

0.21285323

-5.5305096

3.19E-08

1.69E-05

CFI

ENSG00000120337

1000.91183

-1.03E+00

0.15505798

-6.6528189

2.88E-11

4.56E-08

TNFSF18

ENSG00000165092

3357.86352

-1.02E+00

0.12647914

-8.0326286

9.54E-16

3.03E-12

ALDH1A1

ENSG00000158270

672.056722

-9.71E-01

0.17238019

-5.6302976

1.80E-08

1.14E-05

COLEC12

ENSG00000108691

3071.1138

-9.70E-01

0.16099826

-6.0263488

1.68E-09

1.42E-06

ENSG00000141655

271.839886

-9.27E-01

0.25456054

-3.6428714

0.00026961

3.68E-02

CCL2
TNFRSF11
A

ENSG00000165801

275.612365

-8.97E-01

0.24951248

-3.5952761

0.00032405

4.24E-02

ARHGEF40

ENSG00000111339

449.594481

-8.34E-01

0.20054603

-4.1573446

3.22E-05

7.29E-03

ART4

ENSG00000179044

597.448679

-8.32E-01

0.18207129

-4.5714542

4.84E-06

1.46E-03

EXOC3L1

ENSG00000185339

2045.81482

-8.26E-01

0.13540518

-6.0974007

1.08E-09

9.77E-07

TCN2

ENSG00000205502

819.148073

-8.20E-01

0.22562937

-3.632243

0.00028097

3.79E-02

C2CD4B

ENSG00000151012

4060.63317

-7.76E-01

0.14666717

-5.2879169

1.24E-07

5.61E-05

SLC7A11

ENSG00000137507

1984.79427

-7.73E-01

0.13753493

-5.620421

1.90E-08

1.15E-05

LRRC32

ENSG00000128918

420.821593

-7.60E-01

0.20193262

-3.7650566

0.00016651

2.74E-02

ALDH1A2

ENSG00000005108

803.863033

-7.42E-01

0.1664832

-4.4566431

8.33E-06

2.30E-03

THSD7A

ENSG00000154222

924.924761

-7.37E-01

0.20311171

-3.6263785

0.00028742

3.84E-02

CC2D1B

ENSG00000159640

2833.08572

-7.27E-01

0.13001192

-5.5949959

2.21E-08

1.22E-05

ACE

ENSG00000182621

743.292897

-7.11E-01

0.19503798

-3.6437596

0.00026868

3.68E-02

PLCB1

ENSG00000128052

8404.32115

-7.00E-01

0.1136694

-6.1620562

7.18E-10

7.01E-07

KDR

ENSG00000069122

1349.65009

-6.75E-01

0.14560161

-4.6333794

3.60E-06

1.11E-03

ADGRF5

ENSG00000112096

3514.23599

-6.68E-01

0.17974848

-3.7164804

0.00020202

3.07E-02

SOD2

ENSG00000170323

1881.10706

-6.45E-01

0.1546985

-4.1698611

3.05E-05

7.03E-03

FABP4

ENSG00000189221

824.77486

-6.42E-01

0.16453121

-3.9042183

9.45E-05

1.82E-02

MAOA

ENSG00000185070

3810.78858

-6.05E-01

0.14115872

-4.2865627

1.81E-05

4.70E-03

FLRT2

ENSG00000101445

2880.30759

-5.68E-01

0.12449194

-4.5630315

5.04E-06

1.49E-03

PPP1R16B
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ENSG00000100906

1598.15353

-5.52E-01

0.14284274

-3.8665744

0.00011038

2.03E-02

NFKBIA

ENSG00000120885

4198.03674

-5.42E-01

0.12752303

-4.2472826

2.16E-05

5.42E-03

CLU

ENSG00000125266

2397.97689

-5.16E-01

0.1360608

-3.7903846

0.00015041

2.62E-02

EFNB2

ENSG00000173852

3386.38156

-4.96E-01

0.13157754

-3.7689363

0.00016395

2.74E-02

DPY19L1

ENSG00000167671

2455.64308

-4.89E-01

0.13311375

-3.6743535

0.00023845

3.48E-02

UBXN6

ENSG00000140105

6448.63426

-4.87E-01

0.12091255

-4.0288764

5.60E-05

1.17E-02

WARS1

ENSG00000137509

6604.07757

-4.87E-01

0.11862697

-4.1015272

4.10E-05

8.98E-03

PRCP

ENSG00000113555

1551.34199

-4.85E-01

0.13618446

-3.5606847

0.00036989

4.74E-02

PCDH12

ENSG00000130309

11541.5449

-4.65E-01

0.10815847

-4.3006895

1.70E-05

4.60E-03

COLGALT1

ENSG00000091490

2844.23249

-4.64E-01

0.12452639

-3.7229279

0.00019693

3.07E-02

SEL1L3

ENSG00000110799

111048.992

-4.42E-01

0.1029534

-4.2928171

1.76E-05

4.66E-03

VWF

ENSG00000003436

6639.33473

-4.16E-01

0.11516043

-3.6103013

0.00030584

4.04E-02

TFPI

ENSG00000142798

150415.616

-3.89E-01

0.10621257

-3.6659041

0.00024647

3.52E-02

HSPG2

ENSG00000124762

7670.1264

4.15E-01

0.11337507

3.66028578

0.00025193

3.55E-02

CDKN1A

ENSG00000182492

13726.0988

4.53E-01

0.11192617

4.0483092

5.16E-05

1.09E-02

BGN

ENSG00000134250

2345.1412

5.12E-01

0.13528724

3.78209148

0.00015552

2.67E-02

NOTCH2

ENSG00000166073

1558.61309

5.18E-01

0.14084313

3.6758658

0.00023704

3.48E-02

GPR176

ENSG00000149948

4044.85411

5.52E-01

0.11810873

4.67713976

2.91E-06

9.46E-04

HMGA2

ENSG00000152377

14633.1236

5.67E-01

0.12096004

4.69093988

2.72E-06

9.08E-04

SPOCK1

ENSG00000106624

3258.23347

5.68E-01

0.11945835

4.75291138

2.01E-06

7.07E-04

AEBP1

ENSG00000026508

2248.14992

5.73E-01

0.14296751

4.00554371

6.19E-05

1.27E-02

CD44

ENSG00000173597

2273.77964

5.73E-01

0.15704098

3.64937447

0.00026288

3.66E-02

SULT1B1

ENSG00000163453

10657.3348

5.89E-01

0.10847826

5.4309934

5.60E-08

2.63E-05

IGFBP7

ENSG00000137076

15256.9275

6.31E-01

0.11173934

5.64404327

1.66E-08

1.14E-05

TLN1

ENSG00000135596

763.813419

6.64E-01

0.16387353

4.05007799

5.12E-05

1.09E-02

MICAL1

ENSG00000136205

1965.21818

6.70E-01

0.16006608

4.18425307

2.86E-05

6.80E-03

TNS3

ENSG00000102802

1022.89021

6.72E-01

0.16063164

4.18144251

2.90E-05

6.80E-03

MEDAG

ENSG00000137463

591.931053

6.79E-01

0.18210269

3.72801379

0.000193

3.07E-02

MGARP

ENSG00000164237

744.6505

6.87E-01

0.18465221

3.71976233

0.00019941

3.07E-02

CMBL

ENSG00000058729

661.623394

6.92E-01

0.1780192

3.88508294

0.0001023

1.91E-02

RIOK2

ENSG00000104419

813.844009

7.20E-01

0.18821135

3.8233801

0.00013164

2.35E-02

NDRG1

ENSG00000213853

534.861358

7.31E-01

0.20376671

3.58613329

0.00033562

4.34E-02

EMP2

ENSG00000176438

626.176204

7.41E-01

0.18613628

3.98051737

6.88E-05

1.36E-02

SYNE3

ENSG00000042493

1232.92484

7.51E-01

0.16794293

4.47117265

7.78E-06

2.19E-03

CAPG

ENSG00000164176

1846.00677

7.51E-01

0.14914398

5.03662689

4.74E-07

1.82E-04

EDIL3

ENSG00000058085

537.388406

7.53E-01

0.20303128

3.70996898

0.00020729

3.09E-02

LAMC2

ENSG00000110422

1148.78248

7.53E-01

0.20281268

3.71483592

0.00020334

3.07E-02

HIPK3
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ENSG00000128567

11224.646

7.54E-01

0.14876757

5.06628173

4.06E-07

1.61E-04

PODXL

ENSG00000170017

4245.17267

7.75E-01

0.13135229

5.9018274

3.59E-09

2.85E-06

ALCAM

ENSG00000128606

463.967334

7.87E-01

0.20841935

3.77529963

0.00015982

2.70E-02

LRRC17

ENSG00000257103

1011.24753

8.03E-01

0.18945659

4.23799976

2.26E-05

5.50E-03

LSM14A

ENSG00000100979

1043.9293

8.26E-01

0.16175581

5.10843024

3.25E-07

1.37E-04

PLTP

ENSG00000167244

672.855837

8.31E-01

0.17640768

4.70840377

2.50E-06

8.56E-04

IGF2

ENSG00000122861

2039.71415

8.49E-01

0.13724269

6.18881744

6.06E-10

6.41E-07

PLAU

ENSG00000070404

907.394343

8.50E-01

0.17565711

4.8402049

1.30E-06

4.84E-04

FSTL3

ENSG00000136928

318.037015

8.82E-01

0.230182

3.8320666

0.00012707

2.30E-02

GABBR2

ENSG00000135480

7541.39705

8.86E-01

0.1274009

6.95684172

3.48E-12

6.31E-09

KRT7

ENSG00000117152

1998.0236

8.94E-01

0.13707658

6.52432894

6.83E-11

9.63E-08

RGS4

ENSG00000134668

1208.86968

9.06E-01

0.16184649

5.59948036

2.15E-08

1.22E-05

SPOCD1

ENSG00000055163

414.539763

9.85E-01

0.20676131

4.76392303

1.90E-06

6.88E-04

CYFIP2

ENSG00000142173

282.89198

1.01E+00

0.25334933

3.97164385

7.14E-05

1.39E-02

COL6A2

ENSG00000115107

406.782247

1.09E+00

0.20634744

5.27535593

1.32E-07

5.80E-05

STEAP3

ENSG00000156466

174.801706

1.13E+00

0.29087678

3.89531747

9.81E-05

1.86E-02

GDF6

ENSG00000166263

300.420972

1.15E+00

0.30746465

3.72566798

0.0001948

3.07E-02

STXBP4

ENSG00000172260

971.078177

1.18E+00

0.15493531

7.59557985

3.06E-14

6.48E-11

NEGR1

ENSG00000169282

136.94956

1.24E+00

0.3281543

3.78999393

0.00015065

2.62E-02

KCNAB1

ENSG00000095303

480.096711

1.27E+00

0.19689882

6.46808397

9.93E-11

1.26E-07

PTGS1

ENSG00000132470

157.422906

1.27E+00

0.31945966

3.98815633

6.66E-05

1.34E-02

ITGB4

ENSG00000162490

283.662047

1.41E+00

0.25686768

5.47408984

4.40E-08

2.17E-05

DRAXIN

ENSG00000149591

1053.8429

1.72E+00

0.18537703

9.25936363

2.06E-20

1.30E-16

TAGLN

ENSG00000198121

81.8514719

1.77E+00

0.41757138

4.24568193

2.18E-05

5.42E-03

LPAR1

ENSG00000111863

103.548945

1.78E+00

0.38418903

4.64077259

3.47E-06

1.10E-03

ADTRP

ENSG00000140092

614.921263

1.89E+00

0.18470883

10.2580904

1.09E-24

1.38E-20

FBLN5

ENSG00000198768

67.17495

2.00E+00

0.48231197

4.14023541

3.47E-05

7.72E-03

APCDD1L

ENSG00000074047

48.9564553

2.55E+00

0.68282283

3.72863732

0.00019252

3.07E-02

GLI2

ENSG00000038427

93.1004752

2.60E+00

0.51313274

5.06633197

4.06E-07

1.61E-04

VCAN
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